Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Income towards Parent Company (2016 - 2025)

Bioadaptives' Income towards Parent Company history spans 7 years, with the latest figure at -$823346.0 for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 121.46% to -$823346.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.6 million, a 148.01% decrease, with the full-year FY2025 number at -$1.6 million, down 73.26% from a year prior.
  • Income towards Parent Company hit -$823346.0 in Q4 2025 for Bioadaptives, down from -$379502.0 in the prior quarter.
  • Over the last five years, Income towards Parent Company for BDPT hit a ceiling of $19095.0 in Q4 2023 and a floor of -$823346.0 in Q4 2025.
  • Historically, Income towards Parent Company has averaged -$223249.4 across 5 years, with a median of -$177084.0 in 2022.
  • Biggest five-year swings in Income towards Parent Company: soared 106.86% in 2023 and later tumbled 2047.04% in 2024.
  • Tracing BDPT's Income towards Parent Company over 5 years: stood at -$89602.0 in 2021, then tumbled by 210.84% to -$278520.0 in 2022, then soared by 106.86% to $19095.0 in 2023, then tumbled by 2047.04% to -$371788.0 in 2024, then tumbled by 121.46% to -$823346.0 in 2025.
  • Business Quant data shows Income towards Parent Company for BDPT at -$823346.0 in Q4 2025, -$379502.0 in Q3 2025, and -$157914.0 in Q2 2025.